How to analyze the company?LEARNWhat should you know before buying?
Get a brief AI stock analysisSaves ~ 15 minutes of your time

GL

NASDAQ:GLUE
Get a brief AI stock analysisSaves ~ 15 minutes of your time

GL

Monte Rosa Therapeutics IncNASDAQ GLUE Stock Report

Get a brief AI stock analysis
Saves ~ 15 minutes of your time

Price

Market cap $B

Exchange

XNAS - Nasdaq

FAIR VALUE

Is GLUE undervalued compared to its fair value?

The fair value of GLUE stock is hidden USD. Relative to the market price of 4.26 USD Monte Rosa Therapeutics Inc is hidden.

Monte Rosa Therapeutics, Inc. is a biopharmaceutical company. It is engaged in developing a portfolio of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeut...[More about valuation]

Monte Rosa Therapeutics Fair Value

hidden
UNLOCK
What is fair value?

Market cap:

0.268 $B

Price:

4.26 USD

Fair value:

hidden

Max value:

hidden

Min value:

hidden

P/E:

hidden

EPS:

-0.531

FINANCIALS

Monte Rosa Therapeutics financial for reporting period

Income Statement

0.0011 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.035 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.032 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
Revenue analysis

0.0011 B 100%
-0.035 B -3284%
-0.032 B -3005%

Balance Sheet

0.27 B
0.15 B

Financial Position Analysis

Assets

0.27 B
Current Assets
0.2 B
Total non-current assets
0.068 B

Total current liabilities
0.041 B
Total non-current liabilities
0.073 B

Cash Flow Statement

-0.04 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.038 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A

Monte Rosa Therapeutics fundamental analysis for trailing twelve months (TTM)

Profitability Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Solvency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Efficiency Indicators

-74 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%
-351 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%
-49 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Dupont Analysis

Stability Indicators

STOCK ANALYSIS

Is GLUE attractive for investment based on fundamental analysis?

GLUE stock rating is hidden. Monte Rosa Therapeutics is a hidden by Eyestock methodology.

Get GLUE Stock Rating
to complete you analysis
UNLOCK
Learn more about quality score?

Net Profit Margin:

-12 714

Gross Margin:

CFO / Debt ratio:

hidden

Current ratio:

6.376

Debt / Equity ratio:

ROE:

-74

ROIC:

hidden

Stability Ratio (2y):

hidden

Stability Ratio (5y):

hidden

Earnings quality:

hidden

GLUE analysis by AI

Eyebot AI analysis

We carefully consider 10 indicators for GLUE to calculate the final rating score. Use AI leverage to quickly get the main conclusions before diving into the details

Monte Rosa Therapeutics Inc competitors

AB

ABBV

Abbvie Inc

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Ill...

Discover

AM

AMGN

Amgen Inc

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. The Company...

Discover

VR

VRTX

Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs fo...

Discover

Monte Rosa Therapeutics Inc dividends

GLUE dividend metrics

Payout ratio
Dividend yield
Annual dividend
Dividend streak
Average dividend yield over 3 years
Average dividend yield over 5 years

Dividend per share

By years
By payments
1y
3y
5y
All time
This ticker has no dividend history

About GLUE stock

About the company Monte Rosa Therapeutics Inc

Market cap $B

0.268

Dividend yield

Shares outstanding

49.359 B

Monte Rosa Therapeutics, Inc. is a biopharmaceutical company. It is engaged in developing a portfolio of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. It develops a protein degradation platform, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN), that enables it to identify protein targets and molecular glue degrader (MGD), product candidates that are designed to eliminate therapeutically relevant proteins. It focuses on therapeutic targets backed by biological and genetic rationale discovering and developing novel precision medicines. Its lead product candidate is MRT-2359, which is an orally bioavailable degrader of the translation termination factor protein GSPT1 in development initially for use in the treatment of cancers. Its programs are focused on delivering therapies to targets that have been considered undruggable or inadequately drugged in biological pathways.

GLUE profile

  • Ticker

    GLUE

  • Country

    USA

  • Exchange

    XNAS - Nasdaq

  • Report currency

    USD - US dollar

  • IPO date

    24 June 2021

  • Sector

    Healthсare

  • Industry

    Biotechnology

  • Employees

    123

  • City

    Boston

  • Address

    645 Summer Street, Suite 102

  • Cusip

    61225M102